Resistance to EGFR targeting therapies in lung cancer

被引：0

作者：

Watzka, S. B. ^{[1
]}

Posch, F.

Hochmair, M. ^{[2
]}

Setinek, U. ^{[3
]}

Koestler, W. J. ^{[4
,5
]}

Mueller, M. R.

机构：

[1] Otto Wagner Hosp, Div Thorac Surg, Karl Landsteiner Inst Thorac Oncol, A-1140 Vienna, Austria

[2] Otto Wagner Hosp, Div Pulmol 1, A-1140 Vienna, Austria

[3] Otto Wagner Hosp, Div Pathol, A-1140 Vienna, Austria

[4] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria

[5] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria

来源：

MINERVA CHIRURGICA | 2011年 / 66卷 / 05期

关键词：

Non-small cell lung cancer; Receptor; epidermal growth factor; Lung neoplasms; GROWTH-FACTOR-RECEPTOR; KINASE DOMAIN MUTATIONS; K-RAS MUTATIONS; TYROSINE KINASE; ACQUIRED-RESISTANCE; CLINICAL-RESPONSE; DRUG-RESISTANCE; T790M MUTATIONS; KRAS MUTATIONS; GENE-MUTATIONS;

D O I：

暂无

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The treatment of advanced non-small cell lung cancer (NSCLC) by therapies targeting the epidermal growth factor receptor (EGFR) pathway represents one of the most important advances in thoracic oncology. Reversible EGFR tyrosine kinase inhibitors (TKIs), like gefitinib and erlotinib, are able to achieve dramatic responses in a subset of patients. However, most patients treated with TKIs eventually develop resistance against these drugs. Here we review the physiology and pathology of EGFR activation in NSCLC, the clinical experience with TKIs, the mechanisms of resistance against TKIs, and discuss various approaches to treat resistance against TKIs.

引用

页码：483 / 494

页数：12

共 100 条

[1]

Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO

[2]

2-H

[3]

Amann J, 2005, CANCER RES, V65, P226

[4] Phenotype of bone metastases of non-small cell lung cancer:: Epidermal growth factor receptor expression and K-RAS mutational status [J].

Badalian, Gayane ;

Barbai, Tamas ;

Raso, Erzsebet ;

Derecskei, Katalin ;

Szendroi, Miklos ;

Timar, Jozsef .

PATHOLOGY & ONCOLOGY RESEARCH, 2007, 13 (02) :99-104

[5] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[6] Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions [J].

Barr, Sharon ;

Thomson, Stuart ;

Buck, Elizabeth ;

Russo, Suzanne ;

Petti, Filippo ;

Sujka-Kwok, Izabela ;

Eyzaguirre, Alexandra ;

Rosenfeld-Franklin, Maryland ;

Gibson, Neil W. ;

Miglarese, Mark ;

Epstein, David ;

Iwata, Kenneth K. ;

Haley, John D. .

CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (06) :685-693

[7] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[8] The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors [J].

Belani, Chandra P. .

CANCER INVESTIGATION, 2010, 28 (04) :413-423

[9] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [J].

Bell, DW ;

Gore, I ;

Okimoto, RA ;

Godin-Heymann, N ;

Sordella, R ;

Mulloy, R ;

Sharma, SV ;

Brannigan, BW ;

Mohapatra, G ;

Settleman, J ;

Haber, DA .

NATURE GENETICS, 2005, 37 (12) :1315-1316

[10] Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs [J].

Bianco, R. ;

Garofalo, S. ;

Rosa, R. ;

Damiano, V. ;

Gelardi, T. ;

Daniele, G. ;

Marciano, R. ;

Ciardiello, F. ;

Tortora, G. .

BRITISH JOURNAL OF CANCER, 2008, 98 (05) :923-930

← 1 2 3 4 5 6 7 8 9 10 →